🗂️
Archived grant — no longer open
This grant has closed and is kept as a historical reference. Browse current grants for active opportunities.
grant
Nanobarrier contact lenses for mono and combination therapy for treating microbial keratitis
Organization COLORADO SCHOOL OF MINESLocation GOLDEN, UNITED STATESPosted 1 Mar 2024Deadline 28 Feb 2026 ⚠️
NIHUS FederalResearch GrantFY2025Absolute ethanolAcuteAminoglycosidesAnimal ModelAnimal Models and Related StudiesAntibiotic AgentsAntibiotic DrugsAntibiotic ResistanceAntibioticsAqueous HumorBandageBinding ProteinsBioavailabilityBiocompatible MaterialsBiological AvailabilityBiomaterialsBlindnessBody TissuesCase StudyCombined Modality TherapyContact LensesCorneaCorneal infectionCystinosisDataDeveloping CountriesDeveloping NationsDevelopmentDevicesDiminished VisionDiseaseDisorderDomestic RabbitDoseDrainageDrainage procedureDropsDrug DeliveryDrug Delivery SystemsDrug KineticsDrugsDrynessETOHEatingEpitheliumEthanolEthyl AlcoholEyeEye DropsEyeballEyedropsFDA approvedFluoroquinolonesFood IntakeFrequenciesFutureGenerationsGlaucomaGoalsGrain AlcoholHourHydrogelsHydrogen OxideHydrophilic Contact LensesHygroscopicityIn VitroIndividualInfectionInflammationIntraocular FluidInvestigatorsIonsKeratitisLegal patentLess-Developed CountriesLess-Developed NationsLigand Binding ProteinLigand Binding Protein GeneLow VisionMRSAMarketingMath ModelsMeasuresMedicationMethicillin Resistant S. AureusMethylcarbinolMicrobial keratitisMiscellaneous AntibioticModelingModulusMoxifloxacinMultimodal TherapyMultimodal TreatmentNew ZealandO elementO2 elementOryctolagus cuniculusOxygenP aeruginosaP. aeruginosaPartial SightPartition CoefficientPatentsPatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatientsPermeabilityPharmaceutical PreparationsPharmacokineticsPhysiologic AvailabilityPrognosisPropertyProtein BindingPseudomonas aeruginosaPseudomonas pyocyaneaPublicationsRabbitsRabbits MammalsReduced VisionRegimenResearchResearch PersonnelResearchersResistance developmentResistance to antibioticsResistant developmentResistant to antibioticsS aureusS. aureusS. aureus infectionScientific PublicationShapesSiliconesSoft Contact LensesStaph aureusStaph aureus infectionStaphylococcus aureusStaphylococcus aureus infectionSterilizationSubnormal VisionSurvey InstrumentSurveysTestingTherapeuticThird-World CountriesThird-World NationsTimeTissuesTobramycinTobrexUnder-Developed CountriesUnder-Developed NationsVancomycinVariantVariationVisual impairmentVitamin EWaterWettabilityWound Repairantibiotic drug resistanceantibiotic resistantbarrier to translationbiological materialbound proteincase reportcombination therapycombined modality treatmentcombined treatmentcommercializationcornealcystine storage diseasedesigndesigningdeveloping countrydeveloping nationdeveloping resistancedevelopmentaldosagedrug efficacydrug/agentefficacy studyfull scale manufacturingglaucomatoushealingimprovedin vivoinfected with S. aureusinfected with Staph aureusinfected with Staphylococcus aureusinfections in the corneainfectious keratitisinnovateinnovationinnovativeinsightlarge scale manufacturinglarge scale productionlenslensesmanufacturemass productionmathematic modelmathematical modelmathematical modelingmethicillin resistance Staphylococcus aureusmethicillin resistant Staphylococcus aureusmethicillin resistant strains of Staphylococcus aureusmodel of animalmulti-modal therapymulti-modal treatmentnew approachesnovelnovel approachesnovel strategiesnovel strategyobstacle to translationpatient oriented outcomestooltranslation barriertranslation obstacletranslational barriertranslational obstaclevision impairmentvision lossvisual lossvisually impairedwound healingwound recoverywound resolutionα-Tocopherol
Applications closed.
Description preview
Microbial keratitis (MK) is a serious ophthalmic infection that can cause visual impairment and even blindness. The MK
infection is commonly treated by the fourth-generation fluoroquinolones such as moxifloxacin or combination therapy
including tobramycin and vancomycin or gentamycin and vancomycin. The frequency of drop instillation for severe…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click